A novel trinuclear platinum complex overcomes cisplatin resistance an osteosarcoma cell system

Molecular Pharmacology

Volumn 55, Issue 3, 1999, Pages 528-534

  Perego, Paola ^a   Caserini, Claudia ^a   Gatti, Laura ^a   Carenini, Nives ^a   Romanelli, Simona ^a   Supino, Rosanna ^a   Colangelo, Donato ^b   Viano, Ilario ^b   Leone, Roberto ^c   Spinelli, Silvano ^d   Pezzoni, Gabriella ^d   Manzotti, Carla ^d   Farrell, Nicholas ^e   Zunino, Franco ^f  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d Boehringer Mannheim Italia SpA   (Italy)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^f Istituto Nazionale Tumori ^*

Author keywords

[No Author keywords available]

Indexed keywords

BBR 3464; CISPLATIN; PLATINUM COMPLEX; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; COMPLEX FORMATION; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; OSTEOSARCOMA CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARBOPLATIN; CISPLATIN; DNA ADDUCTS; DNA DAMAGE; DNA LIGASES; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; HUMANS; ORGANOPLATINUM COMPOUNDS; OSTEOSARCOMA; TUMOR CELLS, CULTURED;

EID: 0033035638     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R and Howell SB (1996) Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56:3087-3090.
2. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH and Boyd MR (1988) Feasability of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48:589-601.
3. Anthoney DA, McIlwrath AJ, Gallagher WM, Edlin ARM and Brown R (1996) Microsatellite instability, apoptosis and loss of p53 function in drug-resistant tumor cells. Cancer Res 56:1374-1381.
4. Bonetti A, Apostoli P, Zanninelli M, Pavanel F, Colombatti M, Cetto GL, Franceschi T, Sperotto L and Leone R (1996) Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin-or carboplatin-based chemotherapy. Clin Cancer Res 2:1829-1835.
5. Dancey J and Le Chevalier T (1997) Non-small cell lung cancer: An overview of current management. Eur J Cancer 33:2-7.
6. Eastman A and Schulte N (1988) Enhanced DNA repair as a mechanism of resistance to cis-diamminodichloroplatinum(II). Biochemistry 27:4730-4734.
7. Ellman GE (1959) Tissue sulphydryl groups Arch Biochem Biophys 82:70-77.
8. Ewig RAG and Kohn KW (1978) DNA-protein cross-linking and DNA interstrand cross-linking by haloethylnitrosoureas in L1210 cells Cancer Res 38:3197-3203.
9. Farrell N (1996a) Current status of structure-activity relationships of platinum anticancer drugs. Activation of the trans geometry. Metal Ions in Biol Syst 32603.
10. Farrell N (1996b) DNA binding of dinuclear platinum complexes, in Advance in DNA Sequence Specific Agents (Hurley LH and Chaires JB, eds) vol 2, pp 187-216, JAI Press Inc.
11. Farrell N, Qu Y, Kasparkova J, Brabec V, Valsecchi M, Menta E, Di Domenico R, Conti M, Da Re G, Lotto A and Spinelli S (1997) Chemical studies and DNA binding of charged polynuclear platinum complexes. Proc Am Assoc Cancer Res 38:310.
12. Fram RJ, Woda BA, Wilson JM and Robichaud N (1990) Characterization of acquired resistance to cis-diamminedichloroplatinum(II) in BE human colon carcinoma cells. Cancer Res 50:72-77.
13. Gately DP and Howell SB (1993) Cellular accumulation of the anticancer agent cisplatin: A review. Br J Cancer 67:1171-1176.
14. Giuliani FC, Beggiolin G, Piazzoni L, Formento ML, Di Blasi P, Farrell N, Kelland L, Caserini C, Perego P, Supino R and Zunino F (1997) Pattern of cellular sensitivity to BBR 3464, a novel trinuclear platinum complex, in human tumor cell lines: Lack of cross-resistance with cisplatin. Proc Am Assoc Cancer Res 38:310.
15. Johnson SW, Laub PB, Beesley JS, Zols RF and Hamilton TC (1997) Increased platinum-DNA damage tolerance is associated with ciaplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res 57:850-856.
16. Kasahara K, Fujiwara Y, Nishio K, Ohmori T, Sugimoto Y, Komiya K, Matsuda T. and Saijo N (1991) Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to risplatin. Cancer Res 51:3237-3242.
17. Kelland LR, Mistry P, Abel G, Freidlos F, Low SY, Robert JJ and Harrap KR (1992a) Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular non-seminomatous germ cell line. Cancer Res 52:1710-1716.
18. Kelland LR, Murrer BA, Abel G, Giandomenico CM, Mistry P and Harrap KR (1992b) Ammine/amine platinum (IV) dicarboxylates: A novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 52:822-828.
19. Kimura E, Enns RE, Thiebaut F and Howell SB (1993) Regulation of HSP60 mRNA expression in a human ovarian carcinoma cell line. Cancer Chemother Pharmacol 32:279-285.
20. Kohn KW (1979) DNA as a target in cancer chemotherapy: Measurement of macromolecular DMA damage produced in mammalian cells by anticancer agents and carcinogens. Methods Cancer Res 16:291-298.
21. Kohn KW, Ewig RAG, Erickson LC and Zwelling LA (1981) Measurement of strand breaks and cross-links by alkaline elution, in DNA repair: A Laboratory Manual of Research Procedures (Friedberg EC and Hanawalt PC eds) vol 1, part B, pp 370-401, Marcel Dekker, New York.
22. Lindquist S (1989) The heat-shock response. Annu Rev Biochem 55:1151-1191.
23. Loh SY, Mistry P, Kelland LR, Abel G, Murrer BA and Harrap KR (1992) Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: Circumvention studies using novel platinum(II) and (IV) ammine/amine complexes. Br J Cancer 66:1109-1115.
24. Maniatis T, Fritsh EF and Sambrook J (1982) Molecular Cloning: A Laboratoty Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
25. Mellish KJ, Barnard CFJ, Murrer BA and Kelland LR (1995) DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines Int J Cancer 62:717-723.
26. Mistry P, Kelland LR, Abel G, Sidhar S and Harrap KR (1991) The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 64:215-220.
27. Mistry P, Kelland LR, Loh SY, Abel G, Murrer BA and Harrap KR (1992) Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines. Cancer Res 52:6188-6193.
28. Ozols RF and Young RC (1991) Chemotherapy of ovarian cancer. Semin Oncol 18:222-232.
29. Perego P, Capranico G, Supino R and Zunino F (1994) Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types. Anticancer Drugs 5:645-649.
30. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC and Zunino F (1996) Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56:556-562.
31. Perego P, Righetti SC, Supino R, Delia D, Caserini C, Carenini N, Bedognè B, Broome E, Krajewski S, Reed JC and Zunino F (1997) Role of apoptosis and apoptosis-related proteins in the cisplatin-resistant phenotype of human tumor cell lines. Apoptosis 2:540-548.
32. Plooy ACM, Fichtinger-Schepman AMJ, Schutte HH, van Dijk M. and Lohman PHM (1985) The quantitative detection of various Pt-DNA-adducts in chinese hamster ovary cells treated with cisplatin: Application of immunochemical techniques. Carcinogenesis 6:561-566.
33. Pratesi G, Giuliani FC, Polizzi D, Righetti S, Manzotti C, Pezzoni G, Farrell N and Zunino F (1997) Complete lack of cross-resistance of cisplatin-resistant tumors to a novel charged trinuclear platinum complex: p53-independent antitumor efficacy. Proc Am Assoc Cancer Res 38:310.
34. Soranzo C, Perego P and Zunino F (1990) Effect of tumor necrosis factor on human tumor cell lines sensitive and resistant to cytotoxic drugs and its interaction with chemotherapeutic agents. Anticancer Drugs 1:157-163.
35. Wang TSF (1991) Eukaryotic DNA polymerases. Annu Rev Biochem 60:513-552.